INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 435m ago
HOUSE PTR35m ago
SEC 13F35m ago
ROBINHOOD CHAIN34m ago
Corporate insider
KN

Khan Najat

Director, Chief R&D Commercial OfficerCIK 0002020969

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 1
Max Insider Score23
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
KN
Khan NajatDirector, CEO and President
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$254K
80.5K sh
Aug 17, 2026Aug 18, 2026
traded Aug 17, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    RECURSION PHARMACEUTICALS, INC.Director, Chief R&D Commercial Officer · Nov 6, 2025
23
KN
Khan NajatDirector, CEO and President
RXRXRECURSION PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL
$84K
23.6K sh
Jun 5, 2026
Jun 5, 2026
traded Jun 5, 2026
+0d
SEC FORM 4

Evidence

12
KN
Khan NajatDirector, CEO and President
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$191K
62.7K sh
May 15, 2026May 19, 2026
traded May 15, 2026
+4dSEC FORM 4

Evidence

12
KN
Khan NajatDirector, Chief R&D Commercial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Tax withholding
F$73K
17.6K sh
Nov 17, 2025Nov 19, 2025
traded Nov 17, 2025
+2dSEC FORM 4

Evidence

13
KN
Khan NajatDirector, Chief R&D Commercial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Grant or award
A—
84.9K sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC FORM 4

Evidence

9
KN
Khan NajatDirector, Chief R&D Commercial Officer
RXRXRECURSION PHARMACEUTICALS, INC.
Grant or award
A—
169.9K sh
Nov 5, 2025Nov 6, 2025
traded Nov 5, 2025
+1dSEC FORM 4

Evidence